+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Generalized Seizures Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4767443
  • Report
  • April 2019
  • Region: Global
  • 264 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Johnson & Johnson
  • Mylan NV
  • Novartis AG
  • MORE
The global clinical trial report- “2019 Generalized Seizures Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Generalized Seizures. It presents in-depth analysis of Generalized Seizures clinical trials across markets and companies. The research work is for providing complete understanding into trends in Generalized Seizures.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Generalized Seizures clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Generalized Seizures

The research work is prepared through extensive and continuous research on Generalized Seizures trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Generalized Seizures patients are identified
  • The report includes panorama of Generalized Seizures clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Generalized Seizures clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eisai Co Ltd
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Johnson & Johnson
  • Mylan NV
  • Novartis AG
  • MORE
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Generalized Seizures Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Generalized Seizures Clinical Trials by Region
2.2.2 Average Enrollment of Generalized Seizures Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Generalized Seizures Treatment, 2019

3. Region wise Generalized Seizures Clinical Trials
3.1 Asia Pacific Generalized Seizures Clinical Trials by Country
3.2 Europe Generalized Seizures Clinical Trials by Country
3.3 North America Generalized Seizures Clinical Trials by Country
3.4 Middle East and Africa Generalized Seizures Clinical Trials by Country
3.5 South and Central America Generalized Seizures Clinical Trials by Country

4. Generalized Seizures Clinical Trial Trends
4.1 Start Year wise Generalized Seizures Clinical Trials
4.2 Phase wise Generalized Seizures Clinical Trials
4.3 Trial Status wise Generalized Seizures Clinical Trials
4.4 Trial Type wise Generalized Seizures Clinical Trials

5. Generalized Seizures Average Enrollment Trends
5.1 Average Enrollment in Generalized Seizures Trials by Year
5.2 Average Enrollment in Generalized Seizures Trials by Phase
5.3 Average Enrollment in Generalized Seizures Trials by Status
5.4 Average Enrollment in Generalized Seizures Trials by Type of Trial

6. Companies Participating in Generalized Seizures Clinical Trials
6.1 Generalized Seizures Trials by Sponsor Type
6.2 Generalized Seizures Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Generalized Seizures Trials- Phase 1
7.2 Generalized Seizures Trials- Phase 2
7.3 Generalized Seizures Trials- Phase 3
7.4 Generalized Seizures Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Generalized Seizures Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Generalized Seizures Clinical Trials and Enrolment
Figure 5: Europe - Country wise Generalized Seizures Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Generalized Seizures Clinical Trials and Enrolment
Figure 7: North America - Country wise Generalized Seizures Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Generalized Seizures Clinical Trials and Enrolment
Figure 9: Generalized Seizures Clinical Trials by Phase
Figure 10: Generalized Seizures Clinical Trials by Trial Status
Figure 11: Generalized Seizures Clinical Trials by Type
Figure 12: Generalized Seizures Clinical Trials by Sponsor Type
Figure 13: Generalized Seizures Clinical Trials by Leading Sponsors
Figure 14: Generalized Seizures Average Enrollment by Phase
Figure 15: Generalized Seizures Average Enrollment by Trial Status
Figure 16: Generalized Seizures Average Enrollment by Type
Figure 17: Generalized Seizures- Average Enrolment by Type of Sponsors
Figure 18: Generalized Seizures- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Generalized Seizures Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Generalized Seizures Clinical Trials and Enrolment
Table 5: Europe - Country wise Generalized Seizures Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Generalized Seizures Clinical Trials and Enrolment
Table 7: North America - Country wise Generalized Seizures Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Generalized Seizures Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Generalized Seizures Average Enrollment by Phase
Table 15: Generalized Seizures Average Enrollment by Trial Status
Table 16: Generalized Seizures Average Enrollment by Type
Table 17: Generalized Seizures- Average Enrolment by Type of Sponsors
Table 18: Generalized Seizures- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • UCB SA
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co Ltd
  • GlaxoSmithKline Plc
  • GW Pharmaceuticals Plc
  • Johnson & Johnson
  • Mylan NV
  • Novartis AG
  • Parexel International Corp
  • Pfizer Inc
Note: Product cover images may vary from those shown
Adroll
adroll